Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

NCT00433511 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

4994

Enrollment

NIH

Sponsor class

Conditions

Breast Adenocarcinoma

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
OTHER: Placebo Administration
OTHER: Quality-of-Life Assessment

Sponsor

National Cancer Institute (NCI)

Collaborators

Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
North Central Cancer Treatment Group